Table II.

Clonal persistence following adoptive transfer

PBMC Sample DayaLymphocyte Number Per mm3 (days 5–15)Persistence Total (%)bLymphocyte Number Per mm3 (days 23–63)Persistence Total (%)b
Responder
 6(2)c9, 552,085491,64624
 99, 2921,436967,08696
 107, 2312,150943,41084
 167, 613893697314
 17(2)c8, 28555431,32810
 195, 331,956572,74012
 216, 271,407451,07915
 257, 31168564558
 268, 34711444832
 289, 63576741,3827
 30(2)c5, 261116128311
 317, 26739366434
 349, 37826263951
Mean3,258581,70426
SE1,75655159
Nonresponder
 715, 37NDd91,893<1
 118, 358104760<1
 128, 3579158649
 138, 291,073361,027<1
 148, 29532<11,792<1
 157, 34760608715
 1813, 292872385<1
 208, 25548185922
 228, 34305413071
 247, 292,2828753541
 277, 242,496472001
 298, 3216425186<1
Mean913287845
SE22581633
p2 = 0.663ep2 = 0.008p2 = 0.115p2 = 0.001
  • a The days given are relative to the date of TIL infusion.

  • b The values indicate the sum of the percentages of individual clonotypes detected in PBMC samples that were also present in the administered TIL.

  • c Patients 6, 17, and 30 had received a single prior ablation followed by an adoptive transfer of autologous TIL.

  • d A PBL count was not carried out for patient no. 7 at this time point.

  • e The lymphocyte counts and the percentage of persistent clonotypes present in responders and nonresponders were compared using the Wilcoxon rank sum test.